DexCom, Inc. $DXCM Holdings Boosted by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 122.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 484,385 shares of the medical device company’s stock after purchasing an additional 267,118 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.12% of DexCom worth $42,282,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after buying an additional 866,506 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after acquiring an additional 994,300 shares during the period. Geode Capital Management LLC grew its position in shares of DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock worth $936,100,000 after acquiring an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of DexCom in the 1st quarter worth about $554,893,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DXCM shares. Piper Sandler set a $75.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Morgan Stanley reduced their price objective on DexCom from $89.00 to $63.00 and set an “equal weight” rating for the company in a research report on Monday, November 10th. Stifel Nicolaus began coverage on DexCom in a research report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Finally, Cowen reissued a “buy” rating on shares of DexCom in a research note on Friday, October 24th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.62.

Insider Activity

In other news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. The trade was a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 9,999 shares of company stock valued at $619,391 over the last quarter. Insiders own 0.32% of the company’s stock.

DexCom Stock Performance

DXCM opened at $60.23 on Friday. The company has a market capitalization of $23.49 billion, a price-to-earnings ratio of 41.83, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The business has a 50 day moving average price of $65.50 and a two-hundred day moving average price of $76.64.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the firm earned $0.45 EPS. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.